A significant deal on weight loss drug collapsed in less than two months of its commitment, sparking a spat between Danish pharma giant Novo Nordisk and US telehealth platform Hims & Hers Health.
In April 2025, Novo Nordisk and Hims & Hers Health announced a partnership to make the weight-loss drug Wegovy accessible through Hims' platform at £479 ($649) per month and less than two months later on 23 June 2025, Novo abruptly terminated the collaboration, sending Hims' stock plummeting nearly 35 percent.
